Drug that helps MS patients walk faster approved in US
The US Food and Drug Administration (FDA) has approved a drug which has been found to allow with multiple sclerosis (MS) to walk faster, the drug watchdog said.
Multiple sclerosis patients treated with the drug, Ampyra - generic name dalfampridine - were found in clinical trials to have faster walking speeds than those treated with a placebo, the FDA said.
"Trouble with walking is one of the most debilitating problems people with MS face," Russell Katz, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement Saturday.
Ampyra is the first drug approved by the FDA to help improve MS patients' walking.
Multiple sclerosis is a chronic, often disabling disease that affects the brain, spinal cord and optic nerves.
Around 2.5 million people worldwide, including 400,000 in the United States, have MS, according to Multiple Sclerosis Society.
kdz/mk
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies